ACHV vs. RIGL, CDXS, XOMA, IRWD, VSTM, VNDA, SGMO, LXRX, AGEN, and RGLS
Should you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include Rigel Pharmaceuticals (RIGL), Codexis (CDXS), XOMA (XOMA), Ironwood Pharmaceuticals (IRWD), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), Sangamo Therapeutics (SGMO), Lexicon Pharmaceuticals (LXRX), Agenus (AGEN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry.
Achieve Life Sciences vs.
Rigel Pharmaceuticals (NASDAQ:RIGL) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, community ranking, risk, earnings, valuation and institutional ownership.
Rigel Pharmaceuticals presently has a consensus target price of $36.20, indicating a potential upside of 78.77%. Achieve Life Sciences has a consensus target price of $14.80, indicating a potential upside of 365.41%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Achieve Life Sciences is more favorable than Rigel Pharmaceuticals.
Rigel Pharmaceuticals has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Rigel Pharmaceuticals has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500.
Rigel Pharmaceuticals received 129 more outperform votes than Achieve Life Sciences when rated by MarketBeat users. However, 70.46% of users gave Achieve Life Sciences an outperform vote while only 68.90% of users gave Rigel Pharmaceuticals an outperform vote.
66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 9.0% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Achieve Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Rigel Pharmaceuticals has a net margin of 2.46% compared to Achieve Life Sciences' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of -14.80% beat Achieve Life Sciences' return on equity.
In the previous week, Rigel Pharmaceuticals had 3 more articles in the media than Achieve Life Sciences. MarketBeat recorded 4 mentions for Rigel Pharmaceuticals and 1 mentions for Achieve Life Sciences. Rigel Pharmaceuticals' average media sentiment score of 0.96 beat Achieve Life Sciences' score of 0.95 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.
Summary
Rigel Pharmaceuticals beats Achieve Life Sciences on 12 of the 18 factors compared between the two stocks.
Get Achieve Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Achieve Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ACHV) was last updated on 2/21/2025 by MarketBeat.com Staff
